常染色体显性多囊肾病患者颅内动脉瘤的MR血管成像筛查与监测:成本效益分析
该研究构建Markov决策分析模型,从社会视角评估常染色体显性多囊肾病患者颅内动脉瘤的五种MR血管成像筛查与监测策略。基础病例计算显示,每5年MR血管成像筛查并对检出动脉瘤者每年随访为最优策略(成本19839美元,效用25.86质量调整生命年),当预期寿命超过6年时更有利。结论认为MR血管成像筛查具有成本效益,初始阴性后应每5年重复筛查,检出偶然动脉瘤者每年MR血管成像监测为最优,生长中的高风险动脉瘤可考虑治疗。
要点
- 每5年MR血管成像筛查并对检出动脉瘤者每年随访为最优策略,成本19839美元、效用25.86质量调整生命年。
- 初始MR血管成像阴性后应每5年重复筛查。
- 检出偶然颅内动脉瘤者每年MR血管成像监测为最优,生长中的高风险动脉瘤可考虑治疗。
核心结论
- 在常染色体显性多囊肾病患者中,MR血管成像筛查颅内动脉瘤具有成本效益;初始阴性后应每5年重复筛查,检出偶然动脉瘤者每年MR血管成像监测为最优,生长中的高风险动脉瘤可考虑治疗。
研究设计与样本
- 研究构建Markov决策分析模型,从社会视角同时计入成本与结局,评估五种管理策略,并行单因素、双因素和概率敏感性分析。
诊断标准与关键数值
- 基础病例计算显示每5年MR血管成像筛查并对检出动脉瘤者每年随访为最优策略(成本19839美元,效用25.86质量调整生命年),预期寿命超过6年时更有利。
临床应用与阅片要点
- 当颅内动脉瘤患病率大于10%、年破裂风险为0.35%-2.5%、新发动脉瘤检出率低于1.8%时,每5年MR血管成像筛查联合每年MR血管成像随访为有利策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Autosomal dominant polycystic kidney disease (ADPKD) affects one in 400 to one in 1000 individuals; 10%-11% of these individuals have intracranial aneurysms. The frequency and patterns of screening for intracranial aneurysms have not been defined. Purpose To evaluate different MR angiography screening and surveillance strategies for unruptured intracranial aneurysms in patients with ADPKD. Materials and Methods A Markov decision-analytic model was constructed accounting for both costs and outcomes from a societal perspective. Five different management strategies were evaluated: (a) no screening for intracranial aneurysm, (b) one-time screening with annual MR angiography follow-up in patients with intracranial aneurysm, (c) MR angiographic screening every 5 years with endovascular treatment in detected intracranial aneurysm, (d) MR angiography screening every 5 years with annual MR angiography follow-up in patients with intracranial aneurysm, and (e) MR angiography screening every 5 years with biennial follow-up in patients with intracranial aneurysm. One-way, two-way, and probabilistic sensitivity analyses were performed. Results Base case calculation shows that MR angiography screening of patients with ADPKD every 5 years and annual follow-up in patients with detected intracranial aneurysm is the optimal strategy (cost, $19 839; utility, 25.86 quality-adjusted life years), which becomes more favorable as the life expectancy increases beyond 6 years. The conclusion remains robust in probabilistic and one-way sensitivity analyses. When the prevalence of intracranial aneurysms is greater than 10%, annual rupture risk is 0.35%-2.5%, and the rate of de novo aneurysm detection is lower than 1.8%, MR angiography screening every 5 years with annual MR angiography follow-up is the favorable strategy. Conclusion Screening for intracranial aneurysms with MR angiography in patients with autosomal dominant polycystic kidney disease is cost-effective. Repeat screening every 5 years should be performed after a negative initial study. Annual surveillance MR angiography is optimal in patients with detected, incidental intracranial aneurysm, and treatment may be considered in patients with growing, high-risk aneurysms. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Anzai in this issue.
引用
- Malhotra A, Wu X, Matouk CC, et al. MR Angiography Screening and Surveillance for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Cost-effectiveness Analysis. Radiology. 2019. PMID: 30777807. doi:10.1148/radiol.2019181399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。